WEC
AMRX icon

Winslow Evans & Crocker’s Amneal Pharmaceuticals AMRX Stock Holding History

Winslow Evans & Crocker’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-60
Closed -$2K – 1144
2019
Q1 		$2K Buy
+60
New +$793 ﹤0.01% 1090

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Winslow Evans & Crocker's AMRX Position: Q2 2019 in Review

Winslow Evans & Crocker sold out of Amneal Pharmaceuticals (AMRX) in Q2 2019, closing a stake of 60 shares — an estimated $2K sold.

Winslow Evans & Crocker first reported a position in AMRX in Q1 2019 and held it in 1 quarter. The position peaked at $2K in Q1 2019. 129 funds tracked by Wall St. Rank hold AMRX as of Q2 2019.

  • Winslow Evans & Crocker reported no remaining Amneal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Winslow Evans & Crocker sold 60 Amneal Pharmaceuticals shares in Q2 2019, an estimated $2K.
  • Winslow Evans & Crocker first reported a position in Amneal Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Winslow Evans & Crocker's Amneal Pharmaceuticals position peaked at $2K in Q1 2019.
  • 129 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2019.

Based on Winslow Evans & Crocker's 13F filing for Q2 2019, filed 19 Jul 2019.